On-chip cellomics technology for drug screening system using cardiomyocyte cells from human stem cell

2Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Limitation of conventional human Ether-a-go-go Related Gene (hERG) assay and QT prolongation testing for accurate prediction of Torsades de Pointes (TdP) by compounds showed us the necessity of a new approach to evaluate global cardiac safety. As one of the advanced applications of an on-chip cellomics system, on-chip cardiomyocyte cell network-based re-entry model assay has the potential to measure the TdP probability as a pre-clinical test for cardiac safety. This system also can estimate the heart pressure, Na, K, and Ca ion channel conditions using a single cell-based optical/electrical measurement system. In this presentation, we present the system setup and then its possible application for drug discovery and toxicology. © 2010 The Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Yasuda, K. (2010). On-chip cellomics technology for drug screening system using cardiomyocyte cells from human stem cell. Yakugaku Zasshi. Pharmaceutical Society of Japan. https://doi.org/10.1248/yakushi.130.545

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free